Ferring

Robyn Inc. operates a community-driven digital platform that provides women with access to a comprehensive network of integrative maternal wellness tools, resources, and specialists. Founded in 2019 and based in Los Angeles, the company aims to make parental wellness and education accessible by connecting aspiring, expecting, and new parents with virtual providers across various service categories, including birth education, nutrition, mental health, and lactation support. Robyn also offers digital parental education courses, such as childbirth education and lactation classes, alongside pre-pregnancy approved nutrition products. By focusing on destigmatizing and democratizing the journey to parenthood, Robyn supports women in making informed and healthy choices throughout their parental experience.

FerGene is a biotechnology company focused on developing gene therapy treatments for bladder cancer, specifically targeting non-muscle invasive bladder cancer (NMIBC). As a spin-off of Ferring Pharmaceuticals, FerGene aims to commercialize nadofaragene firadenovec in the United States while advancing its global clinical development. The company seeks to leverage innovative science to transform the treatment landscape for bladder cancer, providing urologists with novel therapeutic options that harness the potential of gene therapy.

Biotechnology General is a biopharmaceutical company that creates medical items for humans developed from biotechnology and genetic engineering techniques. They provide analytical methodology for both bacterially-derived and mammalian cell culture-based recombinant proteins undergoing pre-clinical and clinical studies.

Rebiotix, Inc. is a clinical stage biotechnology company based in Roseville, Minnesota, focused on developing therapies for gastrointestinal diseases by leveraging the human microbiome. Founded in 2011, the company specializes in human microbiota restoration therapy, targeting conditions such as clostridium difficile infections, inflammatory bowel disease, and hepatic encephalopathy. Rebiotix's innovative approach involves delivering live, human-derived microbes to the intestinal tract of patients, providing a new method for treating these challenging diseases and recurrent infections. As of April 2018, Rebiotix operates as a subsidiary of Ferring International Center, S.A.

BioSET, Inc. specializes in the research and development of synthetic bioactive peptides aimed at enhancing bone and soft tissue repair. The company offers a range of medical devices, including AMPLEX, an implantable combination device designed for surgical bone graft applications in spine fusion and other orthopedic procedures. BioSET's product portfolio also includes innovations for sports medicine, peptide signaling molecules, and various scaffold biomaterials, all intended for use in musculoskeletal applications such as trauma, fracture repair, and soft tissue treatments. Founded in 2001 and based in Rockville, Maryland, BioSET operates as a subsidiary of Ferring Pharmaceuticals Inc.